Trials
2 active
3 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “autologous cultured chondrocytes on porcine collagen membrane”In the company’s words, NCT03588975 on ClinicalTrials.gov
- Tested for
- Chondral Defect (2 trials), Articular Cartilage Defect (2 trials), Osteochondritis Dissecans (OCD), Articular Cartilage Disorder of Knee
- Main trialPhase 3
- “The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.”In the company’s words, NCT03588975 on ClinicalTrials.gov
Coming up2
- Feb 2030Phase 3 trial completes · ClinicalTrials.gov
- Jul 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2030 | A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee | |
| Phase 3Recruiting | Jul 2030 | A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle | |
| Phase 3Completed | Mar 2012 | Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026